NIOX Group’s (NIOX) “Buy” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft restated their buy rating on shares of NIOX Group (LON:NIOX) in a research report sent to investors on Tuesday morning, Marketbeat.com reports. The firm currently has a GBX 90 ($1.19) target price on the stock.

Separately, Berenberg Bank reaffirmed a “buy” rating and set a GBX 90 ($1.19) target price on shares of NIOX Group in a research report on Tuesday.

NIOX Group Stock Down 0.4 %

NIOX Group stock opened at GBX 58.77 ($0.78) on Tuesday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.94 and a current ratio of 6.31. The stock has a market cap of £24.14 billion, a PE ratio of 2,425.50 and a beta of 0.92. NIOX Group has a fifty-two week low of GBX 53.40 ($0.71) and a fifty-two week high of GBX 80 ($1.06). The firm’s 50-day simple moving average is GBX 65.57 and its 200 day simple moving average is GBX 63.87.

NIOX Group (LON:NIOX) last announced its earnings results on Tuesday, April 1st. The company reported GBX 2.27 ($0.03) earnings per share for the quarter. NIOX Group had a return on equity of 13.29% and a net margin of 28.21%. Research analysts predict that NIOX Group will post 1.1658256 EPS for the current fiscal year.

Insiders Place Their Bets

In other NIOX Group news, insider Jonathan Emms acquired 127,454 shares of the company’s stock in a transaction on Tuesday, April 1st. The shares were acquired at an average cost of GBX 8 ($0.11) per share, with a total value of £10,196.32 ($13,528.35). Company insiders own 46.72% of the company’s stock.

About NIOX Group

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients.